Australia Markets open in 56 mins

Leading brokers name 3 ASX shares to sell today

James Mickleboro
shares to sell

On Monday I looked at three ASX shares that have been given buy ratings by leading brokers this week.

Unfortunately, not all shares are in favour with brokers right now. The three shares listed below have all just been given sell ratings. Here’s why they are bearish on them:

Commonwealth Bank of Australia (ASX: CBA)

According to a note out of Credit Suisse, its analysts have downgraded this banking giant’s shares to an underperform rating with a $77.60 price target. The broker made the move largely on valuation grounds, noting that its shares are trading a lot higher than its current price target. In addition to this, it has downgraded its earnings in response to higher than expected insurance claims. The Commonwealth Bank share price is down slightly at $84.44 on Tuesday.

IOOF Holdings Limited (ASX: IFL)

Analysts at UBS have retained their sell rating and cut the price target on this financial services company’s shares slightly to $6.80. According to the note, IOOF’s first half update was weaker than the broker was expecting. And whilst it acknowledges that FY 2020’s financial results were going to be messy due to acquisitions and divestments, its core earnings are notably lower than its estimates. The IOOF share price has dropped 2% to $7.55 on Tuesday afternoon.

ResMed Inc. (ASX: RMD)

A note out of the Macquarie equities desk reveals that its analysts have held firm with their underperform rating and $17.00 price target on this sleep treatment specialist’s shares. According to the note, although ResMed delivered a second quarter result that was a touch ahead of its expectations, it wasn’t enough to change its view. The broker remains concerned with risks relating to reimbursement rates and regulatory changes. It also notes that competition is increasing in the industry. The ResMed share price is changing hands at $24.61 this afternoon.

The post Leading brokers name 3 ASX shares to sell today appeared first on Motley Fool Australia.

Those may be the shares to sell, but here are the top shares that have just been given buy ratings.

Our Top 3 Blue Chip Shares To Buy Now

You’re invited! For a limited time, The Motley Fool Australia is giving away a fantastic FREE report detailing our 3 TOP BLUE CHIP SHARES to buy and own for now and beyond!.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping grossed-up dividend of over 6%! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!


More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020